Prof. Almond’s appointment will strengthen Osivax’s capacities to drive, position and prioritize pipeline development and especially OVX836, a broad-spectrum influenza vaccine Lyon, France – February 19th, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a breakthrough influenza vaccine, announced today that the Company is strengthening its management team with the appointment of …
Category archives: Press
Osivax appoints Dr. Delphine Guyon-Gellin as Chief Business Development Officer
This recruitment brings strategic capabilities to drive the development of Osivax’s lead candidate, a breakthrough influenza vaccine Lyon, France – January 24th, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a breakthrough influenza vaccine, announced today that the Company is strengthening its management team with the appointment of Dr. Delphine Guyon-Gellin as …
Continue reading “Osivax appoints Dr. Delphine Guyon-Gellin as Chief Business Development Officer”